Abstract
Cancer immunotherapy is based on the premise that activated, pro-inflammatory T cell responses to tumor will mostly combat tumor growth. Nowadays accepted as largely valid, this hypothesis has been formed as a result of extensive theoretical and experimental argumentation on the inherent function of the immune system and the nature of the immunological self, dating back to the foundations of immunology. These arguments have also been affected by how current working hypotheses were set by researchers, an issue that has been the focus of study by medical anthropologists. As a result of these processes, cancer immunotherapy has developed into a truly promising anti-cancer strategy, with very substantial benefits in clinical outcomes. However, as immunotherapy still has large margins for improvement, a more thorough examination of both the historical background and evolutionary context of current assumptions for how the immune system responds to cancer can help reveal novel, testable questions. We describe how attempting to answer some of these questions experimentally, such as identifying the contributors of tumor-associated fibrosis, has led to potentially useful insights on how to improve immunotherapy.
Similar content being viewed by others
Abbreviations
- FuHC:
-
Fusibility/histocompatibility gene product
- RAG:
-
Recombination activating gene
- Treg:
-
Regulatory T
References
Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342:1432–1433. https://doi.org/10.1126/science.342.6165.1432
Tauber AI (1991) The immunological self: a centenary perspective. Perspect Biol Med 35:74–86
Vikhanski L (2016) Immunity. Chicago Review Press, Chicago
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111. https://doi.org/10.1038/35074122
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80. https://doi.org/10.1126/science.aaa6204
Klein G, Sjogren HO, Klein E, Hellstrom KE (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20:1561–1572
Aluvihare VR, Kallikourdis M, Betz AG (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5:266–271. https://doi.org/10.1038/ni1037
Barbee MS, Ogunniyi A, Horvat TZ, Dang TO (2015) Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 49:907–937. https://doi.org/10.1177/1060028015586218
Martin E (1990) Toward an anthropology of immunology: the body as nation state. Med Anthropol Q 4:410–426. https://doi.org/10.1525/maq.1990.4.4.02a00030
Napier AD (2003) The age of immunology: conceiving a future in an alienating world. University of Chicago Press, Chicago
Napier AD (2012) Introduction. Cult Anthropol 27:118–121. https://doi.org/10.1111/j.1548-1360.2012.01129.x
Napier AD (2013) A new sociobiology: immunity, alterity, and the social repertoire. Camb Anthropol 35:20–43. https://doi.org/10.3167/ca.2013.310202
Anderson W (2014) Getting ahead of one’s self? The common culture of immunology and philosophy. Isis 105:606–616
Tauber AI (1994) The immune self: theory or metaphor. Immunol Today 15:134–136. https://doi.org/10.1016/0167-5699(94)90157-0
Tauber AI (1999) The elusive immune self: a case of category errors. Perspect Biol Med 42:459–474
Mantovani A (2016) Reflections on immunological nomenclature: in praise of imperfection. Nat Immunol 17:215–216. https://doi.org/10.1038/ni.3354
Ramos GC (2012) Inflammation as an animal development phenomenon. Clin Dev Immunol 2012:983203. https://doi.org/10.1155/2012/983203
Medawar PB (1953) Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol Med 7:320–338
Billington WD (2003) The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. J Reprod Immunol 60:1–11
Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042–1049
Cohn M (1994) The wisdom of hindsight. Annu Rev Immunol 12:1–62. https://doi.org/10.1146/annurev.iy.12.040194.000245
Cohn M (2010) The evolutionary context for a self-nonself discrimination. Cell Mol Life Sci 67:2851–2862. https://doi.org/10.1007/s00018-010-0438-z
Cohn M (2015) Analysis of Paris meeting redefining the “Self” of the immune system. Immunol Res 62:106–124. https://doi.org/10.1007/s12026-015-8641-5
Lafferty KJ, Cunningham AJ (1975) A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 53:27–42
Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C:373–389
Varela FJ, Coutinho A, Dupire B, Vaz N (1988) Cognitive networks: immune, neural, and otherwise. In: Perelson A (ed) Theoretical immunology, Part II. Addison-Wesley, New Jersey, pp 359–375
Cohen IR, Young DB (1991) Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 12:105–110. https://doi.org/10.1016/0167-5699(91)90093-9
Pradeu T, Jaeger S, Vivier E (2013) The speed of change: towards a discontinuity theory of immunity. Nat Rev Immunol 13:764–769. https://doi.org/10.1038/nri3521
Schneider DS, Ayres JS (2008) Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol 8:889–895. https://doi.org/10.1038/nri2432
Råberg L, Graham AL, Read AF (2009) Decomposing health: tolerance and resistance to parasites in animals. Philos Trans R Soc Lond B Biol Sci 364:37–49. https://doi.org/10.1098/rstb.2008.0184
Sears BF, Rohr JR, Allen JE, Martin LB (2011) The economy of inflammation: when is less more. Trends Parasitol 27:382–387. https://doi.org/10.1016/j.pt.2011.05.004
Medzhitov R, Schneider DS, Soares MP (2012) Disease tolerance as a defense strategy. Science 335:936–941. https://doi.org/10.1126/science.1214935
Janeway CA (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54(Pt 1):1–13
Janeway CA (1992) The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13:11–16. https://doi.org/10.1016/0167-5699(92)90198-G
Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991–1045. https://doi.org/10.1146/annurev.iy.12.040194.005015
Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305
Medzhitov R, Preston-Hurlburt P, Janeway CA (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394–397. https://doi.org/10.1038/41131
Medzhitov R, Janeway CAJ (2000) How does the immune system distinguish self from nonself. Sem Immunol 12:185–188
Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036
Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B (1995) T cell awareness of paternal alloantigens during pregnancy. Science 270:630–633
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059. https://doi.org/10.1038/nm1622
Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P (2007) Toll-like receptor 3 expressed by melanoma cells as a target for therapy. Clin Cancer Res 13:4565–4574. https://doi.org/10.1158/1078-0432.CCR-07-0274
Gonzalez-Gugel E, Saxena M, Bhardwaj N (2016) Modulation of innate immunity in the tumor microenvironment. Cancer Immunol Immunother 65:1261–1268. https://doi.org/10.1007/s00262-016-1859-9
Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M et al (2014) TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res 74:5008–5018. https://doi.org/10.1158/0008-5472.CAN-13-2698
Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247–250
Aluvihare VR, Kallikourdis M, Betz AG (2005) Tolerance, suppression and the fetal allograft. J Mol Med 83:88–96
Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057–1061
Garetto S, Trovato AE, Lleo A, Sala F, Martini E, Betz AG et al (2015) Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. Immunobiology 220:1025–1029. https://doi.org/10.1016/j.imbio.2015.02.006
Littman DR, Rudensky AY (2010) Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140:845–858. https://doi.org/10.1016/j.cell.2010.02.021
Kahn DA, Baltimore D (2010) Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance. Proc Natl Acad Sci USA 107:9299–9304
Rowe JH, Ertelt JM, Xin L, Way SS (2012) Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 490:102–106. https://doi.org/10.1038/nature11462
Magor BG, De Tomaso A, Rinkevich B, Weissman IL (1999) Allorecognition in colonial tunicates: protection against predatory cell lineages? Immunol Rev 167:69–79
De Tomaso AW, Nyholm SV, Palmeri KJ, Ishizuka KJ, Ludington WB, Mitchel K et al (2005) Isolation and characterization of a protochordate histocompatibility locus. Nature 438:454–459. https://doi.org/10.1038/nature04150
Alder MN, Rogozin IB, Iyer LM, Glazko GV, Cooper MD, Pancer Z (2005) Diversity and function of adaptive immune receptors in a jawless vertebrate. Science 310:1970–1973
Dzik JM (2010) The ancestry and cumulative evolution of immune reactions. Acta Biochim Pol 57:443–466
Andersen KG, Nissen JK, Betz AG (2012) Comparative genomics reveals key gain-of-function events in Foxp3 during regulatory T Cell evolution. Front Immunol 3:113. https://doi.org/10.3389/fimmu.2012.00113
Munoz-Suano A, Kallikourdis M, Sarris M, Betz AG (2012) Regulatory T cells protect from autoimmune arthritis during pregnancy. J Autoimmun 38:J103–J108. https://doi.org/10.1016/j.jaut.2011.09.007
Kallikourdis M, Betz AG (2007) Periodic accumulation of regulatory T cells in the uterus: preparation for the implantation of a semi-allogeneic fetus? PLoS One 2:e382
Benedusi V, Martini E, Kallikourdis M, Villa A, Meda C, Maggi A (2015) Ovariectomy shortens the life span of female mice. Oncotarget 6:10801–10811
Weinhold M, Sommermeyer D, Uckert W, Blankenstein T (2007) Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity. J Immunol 179:5534–5542
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469. https://doi.org/10.1126/science.aaf1490
Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146. https://doi.org/10.1038/nrc3670
Stewart TJ, Smyth MJ (2011) Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 30:125–140. https://doi.org/10.1007/s10555-011-9280-5
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C et al (2015) Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350:1079–1084. https://doi.org/10.1126/science.aad1329
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM et al (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350:1084–1089. https://doi.org/10.1126/science.aac4255
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow. Lancet 357:539–545. https://doi.org/10.1016/S0140-6736(00)04046-0
Balkwill FR, Mantovani A (2012) Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22:33–40. https://doi.org/10.1016/j.semcancer.2011.12.005
Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR et al (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25:719–734. https://doi.org/10.1016/j.ccr.2014.04.005
Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D et al (2011) Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 208:1949–1962. https://doi.org/10.1084/jem.20101956
Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20:607–615. https://doi.org/10.1038/nm.3541
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563–567. https://doi.org/10.1038/nature14011
Qin Z, Kim HJ, Hemme J, Blankenstein T (2002) Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 195:1479–1490
Peranzoni E, Rivas-Caicedo A, Bougherara H, Salmon H, Donnadieu E (2013) Positive and negative influence of the matrix architecture on antitumor immune surveillance. Cell Mol Life Sci 70:4431–4448. https://doi.org/10.1007/s00018-013-1339-8
Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A et al (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122:899–910. https://doi.org/10.1172/JCI45817
Salmon H, Donnadieu E (2012) Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix. Oncoimmunology 1:992–994. https://doi.org/10.4161/onci.20239
Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT et al (2008) Collagen density promotes mammary tumor initiation and progression. BMC Med 6:11. https://doi.org/10.1186/1741-7015-6-11
Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418–429. https://doi.org/10.1016/j.ccr.2012.01.007
Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12:269–281. https://doi.org/10.1038/nri3191
Garetto S, Sardi C, Martini E, Roselli G, Morone D, Angioni R et al (2016) Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model. Oncotarget 7:43010–43026. https://doi.org/10.18632/oncotarget.9280
Zhang H, Maric I, Diprima MJ, Khan J, Orentas RJ, Kaplan RN et al (2013) Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 122:1105–1113. https://doi.org/10.1182/blood-2012-08-449413
Marra F, Aleffi S, Galastri S, Provenzano A (2009) Mononuclear cells in liver fibrosis. Semin Immunopathol 31:345–358. https://doi.org/10.1007/s00281-009-0169-0
Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M et al (2007) Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 179:3926–3936
De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H et al (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208:469–478. https://doi.org/10.1084/jem.20101876
Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659. https://doi.org/10.1056/NEJM198612253152606
Gawronska-Kozak B, Bogacki M, Rim JS, Monroe WT, Manuel JA (2006) Scarless skin repair in immunodeficient mice. Wound Repair Regen 14:265–276. https://doi.org/10.1111/j.1743-6109.2006.00121.x
Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF et al (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17:1290–1297
Caserta S, Kleczkowska J, Mondino A, Zamoyska R (2010) Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens. J Immunol 185:6545–6554. https://doi.org/10.4049/jimmunol.1001867
Wynn TA (2003) IL-13 effector functions. Annu Rev Immunol 21:425–456. https://doi.org/10.1146/annurev.immunol.21.120601.141142
Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D et al (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204:1037–1047. https://doi.org/10.1084/jem.20061120
Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F et al (2011) Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 208:479–490. https://doi.org/10.1084/jem.20102131
Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM (2015) TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res 3:518–525. https://doi.org/10.1158/2326-6066.CIR-14-0232
Kallikourdis M, Martini E, Carullo P, Sardi C, Roselli G, Greco CM et al (2017) T cell costimulation blockade blunts pressure overload-induced heart failure. Nat Commun 8:14680. https://doi.org/10.1038/ncomms14680
Acknowledgements
The author is indebted to Dr. A.G. Betz, Dr. D. Kallikourdis, and Prof. M. Holbraad for initiating discussions on the definition of immunological self and pregnancy, postulate identification in scientific theory, and medical anthropology, respectively. The author is also grateful to Prof. A. Mantovani, Prof. S. Meri, Dr. G.C. Ramos, and the reviewers for helpful suggestions and critical reading of the manuscript.
Funding
Aspects of the work described in this review received support from Associazione Italiana per la Ricerca su Cancro (AIRC) (MFAG10752), the Italian Ministry of Health (GR-2009-1558698 and GR-2013-02355011), Fondazione Veronesi as well as Fondazione Cariplo (2014-1184).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares to have no conflicts of interest.
Ethical approval and ethical standards
The data shown in this review have been authorized by the institutional animal welfare committee of the Humanitas Clinical and Research Center, as well as by the Italian Ministry of Health (authorization code 39/2014-PR).
Additional information
This paper is a Focussed Research Review based on a presentation given at the Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, held in Siena, Italy, 13th–15th October 2016. It is part of a series of Focussed Research Reviews and meeting report in Cancer Immunology, Immunotherapy.
Rights and permissions
About this article
Cite this article
Kallikourdis, M. T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy. Cancer Immunol Immunother 67, 989–998 (2018). https://doi.org/10.1007/s00262-017-2113-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-017-2113-9